IL198592A - Proteins linked to 4ig – b7h3, nucleic acids encode it, and methods for creating and using it - Google Patents

Proteins linked to 4ig – b7h3, nucleic acids encode it, and methods for creating and using it

Info

Publication number
IL198592A
IL198592A IL198592A IL19859209A IL198592A IL 198592 A IL198592 A IL 198592A IL 198592 A IL198592 A IL 198592A IL 19859209 A IL19859209 A IL 19859209A IL 198592 A IL198592 A IL 198592A
Authority
IL
Israel
Prior art keywords
production
methods
nucleic acids
acids encoding
encoding same
Prior art date
Application number
IL198592A
Other languages
English (en)
Hebrew (he)
Other versions
IL198592A0 (en
Original Assignee
Macrogenics West Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrogenics West Inc filed Critical Macrogenics West Inc
Publication of IL198592A0 publication Critical patent/IL198592A0/en
Publication of IL198592A publication Critical patent/IL198592A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL198592A 2006-11-08 2009-05-06 Proteins linked to 4ig – b7h3, nucleic acids encode it, and methods for creating and using it IL198592A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85811306P 2006-11-08 2006-11-08
US99388207P 2007-09-14 2007-09-14
PCT/US2007/023620 WO2008066691A2 (en) 2006-11-08 2007-11-08 Tes7 and antibodies that bind thereto

Publications (2)

Publication Number Publication Date
IL198592A0 IL198592A0 (en) 2011-08-01
IL198592A true IL198592A (en) 2015-11-30

Family

ID=39468449

Family Applications (1)

Application Number Title Priority Date Filing Date
IL198592A IL198592A (en) 2006-11-08 2009-05-06 Proteins linked to 4ig – b7h3, nucleic acids encode it, and methods for creating and using it

Country Status (7)

Country Link
US (2) US7718774B2 (enExample)
EP (1) EP2094307A4 (enExample)
JP (1) JP5601836B2 (enExample)
AU (1) AU2007325872B2 (enExample)
CA (1) CA2668800A1 (enExample)
IL (1) IL198592A (enExample)
WO (1) WO2008066691A2 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010080538A1 (en) 2008-12-19 2010-07-15 Macrogenics, Inc. Covalent diabodies and uses thereof
WO2008057632A1 (en) * 2006-11-09 2008-05-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Differential gene expression in physiological and pathological angiogenesis
WO2008100934A1 (en) * 2007-02-14 2008-08-21 Mayo Foundation For Medical Education And Research B7-h3 in cancer
WO2009151717A2 (en) 2008-04-02 2009-12-17 Macrogenics, Inc. Bcr-complex-specific antibodies and methods of using same
KR20110049802A (ko) 2008-07-25 2011-05-12 인스티튜트 포 리서치 인 바이오메드슨 중화 항-인플루엔자 ａ 바이러스 항체 및 이의 용도
US8871207B2 (en) 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
US9347043B2 (en) 2008-10-22 2016-05-24 Institute For Research In Biomedicine Methods for producing antibodies from plasma cells
TWI404931B (zh) * 2009-02-20 2013-08-11 Nat Synchrotron Radiation Res Ct 癌化生物樣本之檢測方法及其使用之檢驗試劑
CA2729593A1 (en) * 2009-02-20 2010-08-26 John Wayne Cancer Institute B7-h3 as a biomarker for diagnosing the progression and early lymph node metastasis of cancer
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
PH12018501083A1 (en) * 2010-03-04 2019-02-18 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
WO2012004410A1 (en) * 2010-07-09 2012-01-12 Oslo Universitetssykehus Hf B7-h3 antagonists and taxanes
MX339622B (es) 2010-08-02 2016-06-02 Macrogenics Inc Diacuerpos covalentes y sus usos.
KR102125672B1 (ko) 2011-04-25 2020-06-23 다이이찌 산쿄 가부시키가이샤 항 ｂ７-ｈ３항체
EP2703486B1 (en) 2011-04-25 2018-03-07 Daiichi Sankyo Company, Limited Anti-b7-h3 antibody
EP2714079B2 (en) 2011-05-21 2019-08-28 MacroGenics, Inc. Deimmunized serum-binding domains and their use for extending serum half-life
LT2734545T (lt) 2011-07-18 2019-05-10 Institute For Research In Biomedicine Antikūnai, neutralizuojantys influenza a virusą, ir jų panaudojimo būdai
KR101935088B1 (ko) 2012-08-24 2019-01-04 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Ror1 암을 치료하고 전이를 저해하는데 이용을 위한 항체와 백신
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
LT3052192T (lt) 2013-10-02 2020-12-10 Medimmune, Llc Neutralizuojantys antikūnai prieš gripą a ir jų naudojimas
US10100115B2 (en) 2014-02-14 2018-10-16 Macrogenics, Inc. Methods for the treatment of vascularizing cancers
AU2015289805B2 (en) 2014-07-15 2020-06-25 Humabs Biomed Sa Neutralizing anti-influenza B antibodies and uses thereof
PL3303384T3 (pl) 2015-06-01 2022-01-03 Medimmune, Llc Neutralizujące cząsteczki wiążące przeciw grypie i ich zastosowania
BR112018006817A2 (pt) 2015-10-08 2018-10-23 Macrogenics Inc método de tratamento do câncer
CA3010313A1 (en) 2016-01-13 2017-07-20 Medimmune, Llc Method of treating influenza a
EP3442574A4 (en) 2016-04-15 2019-12-11 MacroGenics, Inc. Novel B7-H3 binding MOLECULES, ANTIBODY-ACTIVE CONJUGATES AND METHOD OF USE THEREOF
CN109963870B (zh) * 2016-06-08 2023-07-28 艾伯维公司 抗b7-h3抗体和抗体药物偶联物
IL299099B2 (en) 2016-06-27 2025-07-01 Univ California Cancer treatment combinations
BR112019019111A2 (pt) 2017-03-31 2020-05-05 Jiangsu Hengrui Medicine Co anticorpo de b7-h3, seu fragmento de ligação ao antígeno e seu uso médico
MX2021003446A (es) 2018-09-30 2021-06-15 Jiangsu Hansoh Pharmaceutical Group Co Ltd Conjugado analogo del anticuerpo anti-bth3 y exatecan, y uso medicinal del mismo.
CN119080930A (zh) 2019-07-11 2024-12-06 纪念斯隆凯特琳癌症中心 Dll3靶向抗体及其用途
WO2021076886A1 (en) 2019-10-18 2021-04-22 The Regents Of The University Of California 3-phenylsulphonyl-quinoline derivatives as agents for treating pathogenic blood vessels disorders
US20240118284A1 (en) * 2019-10-18 2024-04-11 The Regents Of The University Of California Compositions and methods for detecting plxdc1 and plxcd2 in human tissues
CN120093941A (zh) 2021-02-09 2025-06-06 苏州宜联生物医药有限公司 生物活性物偶联物及其制备方法和用途

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3862925A (en) * 1973-07-05 1975-01-28 American Home Prod Preparation of somatotropin release inhibiting factor and intermediates therefor
US3842067A (en) 1973-07-27 1974-10-15 American Home Prod Synthesis of(des-asn5)-srif and intermediates
JPS5726506B2 (enExample) * 1974-03-08 1982-06-04
US4105603A (en) * 1977-03-28 1978-08-08 The Salk Institute For Biological Studies Peptides which effect release of hormones
USRE30548E (en) * 1979-08-31 1981-03-17 The Salk Institute For Biological Studies Peptides which effect release of hormones
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6054561A (en) 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
US5807715A (en) * 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5552391A (en) 1990-01-16 1996-09-03 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
GB9115364D0 (en) * 1991-07-16 1991-08-28 Wellcome Found Antibody
AU669124B2 (en) * 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
US5565332A (en) * 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US5532159A (en) * 1994-04-01 1996-07-02 The Ohio State University Monoclonal antibody to canine placental oncofetal protein for detecting cancer
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
US6440733B1 (en) * 1996-02-15 2002-08-27 Chugai Seiyaku Kabushiki Kaisha Monoclonal antibodies recognizing antigens on the surface of endothelial cells of tumor vessel
WO2000068266A1 (en) 1999-05-11 2000-11-16 Eli Lilly And Company Amyloid precursor protein protease and related nucleic acid compounds
EP2360254A1 (en) 1999-08-23 2011-08-24 Dana-Farber Cancer Institute, Inc. Assays for screening anti-pd-1 antibodies and uses thereof
US6429303B1 (en) * 1999-09-03 2002-08-06 Curagen Corporation Nucleic acids encoding members of the human B lymphocyte activation antigen B7 family and methods of using the same
US6406840B1 (en) 1999-12-17 2002-06-18 Biomosaic Systems, Inc. Cell arrays and the uses thereof
US20060154313A1 (en) * 2000-04-13 2006-07-13 Immunex Corporation Human B7 polypeptide B7-H3A
WO2001089567A1 (en) 2000-05-22 2001-11-29 Idec Pharmaceuticals Corporation Identification of unique binding interactions between certain antibodies and the human b7.1 and b7.2 co-stimulatory antigens
WO2001094413A2 (en) * 2000-06-06 2001-12-13 Bristol-Myers Squibb Company B7-related nucleic acids and polypeptides and their uses for immunomodulation
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
AU2001283507A1 (en) * 2000-07-27 2002-02-13 Mayo Foundation For Medical Education And Research B7-h3 and b7-h4, novel immunoregulatory molecules
JPWO2002022683A1 (ja) * 2000-09-12 2004-01-22 麒麟麦酒株式会社 新規樹状細胞膜分子及びその用途
US20030134283A1 (en) * 2000-10-03 2003-07-17 Peterson David P. Genes regulated in dendritic cell differentiation
US20070015144A9 (en) * 2001-05-25 2007-01-18 Genset, S.A. Human cDNAs and proteins and uses thereof
EP1401999A4 (en) * 2001-05-25 2005-09-14 Amgen Inc PROTEIN-2 MOLECULES ASSOCIATED WITH B7 AND USE THEREOF
IL159015A0 (en) * 2001-05-25 2004-05-12 Genset Sa Polypeptides, their preparation and use
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
AU2002347761A1 (en) * 2001-08-02 2003-02-24 Eli Lilly And Company Novel polypeptide analogs and fusions and their methods of use
US20040162236A1 (en) * 2002-04-01 2004-08-19 John Alsobrook Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2004001381A2 (en) 2002-06-19 2003-12-31 Raven Biotechnologies, Inc. Novel raag10 cell surface target and a family of antibodies recognizing that target
JP2005530856A (ja) * 2002-06-21 2005-10-13 ジョンズ ホプキンス ユニバーシティー スクール オブ メディシン 膜関連腫瘍内皮マーカー
AU2003248933A1 (en) 2002-07-11 2004-02-02 Incyte Corporation Secreted proteins
WO2004023973A2 (en) 2002-09-12 2004-03-25 Incyte Corporation Molecules for diagnostics and therapeutics
AU2004277368B2 (en) * 2003-03-07 2011-01-20 Dsm Ip Assets B.V. Hydrolases, nucleic acids encoding them and mehods for making and using them
US20050002935A1 (en) * 2003-04-17 2005-01-06 Vincent Ling Use of B7-H3 as an immunoregulatory agent
US20050070474A1 (en) * 2003-04-28 2005-03-31 Krissansen Geoffrey Wayne Methods of treatment and compositions therefor
CA2463487A1 (en) * 2003-04-28 2004-10-28 Auckland Uniservices Limited Tumours treating combinations, compositions and methods
WO2005017163A2 (en) 2003-08-15 2005-02-24 Imperial College Innovations Limited Phenotypic knockout of cell-surface proteins
EP1773884B1 (en) 2004-08-03 2012-03-07 Innate Pharma Therapeutic and diagnostic methods and compositions targeting 4ig-b7-h3 and its counterpart nk cell receptor
US20090297495A1 (en) 2005-03-08 2009-12-03 Verenium Corporation Hydrolases, nucleic acids encoding them and methods for improving paper strength
BRPI0611766A2 (pt) * 2005-06-08 2011-12-20 Dana Farber Cancer Inst Inc métodos e composições para o tratamento de infecções persistentes e cáncer por inibição da rota de morte celular programada
CA2632682A1 (en) * 2005-12-08 2007-06-14 University Of Louisville Research Foundation, Inc. In vivo cell surface engineering
AU2007257692B2 (en) 2006-06-12 2013-11-14 Aptevo Research And Development Llc Single-chain multivalent binding proteins with effector function

Also Published As

Publication number Publication date
US7718774B2 (en) 2010-05-18
US20080226634A1 (en) 2008-09-18
US20100183605A1 (en) 2010-07-22
IL198592A0 (en) 2011-08-01
EP2094307A2 (en) 2009-09-02
EP2094307A4 (en) 2015-08-26
US8216570B2 (en) 2012-07-10
WO2008066691A3 (en) 2008-07-17
AU2007325872B2 (en) 2012-12-13
CA2668800A1 (en) 2008-06-05
JP5601836B2 (ja) 2014-10-08
JP2010508847A (ja) 2010-03-25
WO2008066691A2 (en) 2008-06-05
AU2007325872A1 (en) 2008-06-05

Similar Documents

Publication Publication Date Title
IL198592A (en) Proteins linked to 4ig – b7h3, nucleic acids encode it, and methods for creating and using it
IL195191A (en) Digested Proteins, Nucleic Acids Encoded, and the Process of Creating
PH12007501986B1 (en) Cellulases, nucleic acids encoding them and methods for making and using them
ZA200901875B (en) Phytases, nucleic acids encoding them and methods for making and using them
PT2057274E (pt) Fosfolípases, ácidos nucleicos que as codificam e métodos de preparação e utilização das mesmas
PL1989302T4 (pl) Ksylanazy, kodujące je kwasy nukleinowe i sposoby ich wytwarzania i stosowania
ZA201304283B (en) Xylanases,nucleic acids encoding them and methods for making and using them
PL3101128T3 (pl) Amylazy i glukoamylazy, kwasy nukleinowe kodujące te związki oraz sposoby wytwarzania tych związków oraz stosowania ich
PT1748954T (pt) Fosfolipases, ácidos nucleicos codificando-as e métodos para a sua produção e utilização
IL198379A0 (en) Antibodies binding sphingosine-1-phosphate, nucleic acids encoding the same, and compositions containing the same
EP1869174A4 (en) LYASE ENZYMES, NUCLEIC ACIDS FOR THEIR CODING AND METHOD FOR THEIR PREPARATION AND USE
ZA201405521B (en) Plant co2 sensors,nucleic acids encoding them ,and methods for making and using them
EP1989301A4 (en) CELLULOLYTIC ENZYMES, NUCLEIC ACIDS ENCODING SAME, AND METHODS FOR PREPARING AND USING SAME
IL202443B (en) Nucleic acid encoding it and a pharmaceutical preparation containing the protein, a fusion protein for nucleic acid
EP1910534A4 (en) DNA-BINDING PROTEIN-POLYMERASE CHIMERAE
GB0709333D0 (en) Binding protein
PL2041282T3 (pl) Kwasy nukleinowe wiążące sdf-i
EP2238261A4 (en) ISOMERASES, NUCLEIC ACIDS ENCODING THEM AND METHODS OF MAKING THE USE THEREOF
EP2099932A4 (en) NUCLEIC ACIDS ENCODING THE RECOMBINANT PROTEIN A
EP2024848A4 (en) PROCESS CODE
EP2029739A4 (en) LYASE ENZYMES, NUCLEIC ACIDS FOR THEIR CODING AND METHOD FOR THEIR PREPARATION AND USE
GB0602992D0 (en) Methods, genes and proteins
IL193699A0 (en) Proteins, nucleic acids and medicaments
PL2158095T3 (pl) Element płaski i sposób jego wytwarzania
EP2115153A4 (en) NITRILASES, NUCLEIC ACIDS CODED THEREFOR, AND METHOD FOR THEIR PRODUCTION AND USE

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed